Hydroxyurea can be used to increase mouse c-kit+Thy-1. 1(lo)Lin-/loSca-1(+) hematopoietic cell number and frequency in cell cycle in vivo.
The DNA synthesis inhibitor hydroxyurea (HU) was administered to determine whether it induces changes in the cell-cycle status of primitive hematopoietic stem cells (HSCs)/progenitors. Administration of HU to mice leads to bone marrow accumulation of c-kit+Thy-1.1(lo)Lin-/loSca-1(+) (KTLS) cells in S/G2/M phases of the cell cycle. HU is a relatively nontoxic, reversible cell-cycle agent that can lead to approximately a threefold expansion of KTLS cells in vivo and approximately an eightfold increase in the number of KTLS cells in S/G2/M. HSCs in HU-treated mice have undiminished multilineage long-term and short-term clonal reconstitution activity.
Uchida
N
N
SyStemix Inc, Palo Alto, CA 94304, USA.
Friera
A M
AM
He
D
D
Reitsma
M J
MJ
Tsukamoto
A S
AS
Weissman
I L
IL
D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002452:Cell Count; D002453:Cell Cycle; D002469:Cell Separation; D002478:Cells, Cultured; D005434:Flow Cytometry; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects; D006918:Hydroxyurea / Q000494:pharmacology*; D051379:Mice; D019384:Nucleic Acid Synthesis Inhibitors / Q000494:pharmacology*; D018800:Thy-1 Antigens / Q000032:analysis*; D014700:Verapamil / Q000494:pharmacology
D002121:Calcium Channel Blockers; D019384:Nucleic Acid Synthesis Inhibitors; D018800:Thy-1 Antigens; D014700:Verapamil; D006918:Hydroxyurea